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Abstract
Thrombocytopenia in methotrexate (MTX)-treated cancer and rheumatoid arthritis (RA)
patients connotes the interference of MTX with platelets. Hence, it seemed appealing to
appraise the effect of MTX on platelets. Thereby, the mechanism of action of MTX on plate-
lets was dissected. MTX (10 μM) induced activation of pro-apoptotic proteins Bid, Bax and
Bad through JNK phosphorylation leading to ΔΨm dissipation, cytochrome c release and
caspase activation, culminating in apoptosis. The use of specific inhibitor for JNK abrogates
the MTX-induced activation of pro-apoptotic proteins and downstream events confirming
JNK phosphorylation by MTX as a key event. We also demonstrate that platelet mitochon-
dria as prime sources of ROS which plays a central role in MTX-induced apoptosis. Further,
MTX induces oxidative stress by altering the levels of ROS and glutathione cycle. In paral-
lel, the clinically approved thiol antioxidant N-acetylcysteine (NAC) and its derivative N-
acetylcysteine amide (NACA) proficiently alleviate MTX-induced platelet apoptosis and oxi-
dative damage. These findings underpin the dearth of research on interference of therapeu-
tic drugs with platelets, despite their importance in human health and disease. Therefore,
the use of antioxidants as supplementary therapy seems to be a safe bet in pathologies
associated with altered platelet functions.
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Introduction
Methotrexate (MTX) is a well-known anti-cancer and disease modifying anti-rheumatic drug,
actively used in the treatment of a wide spectrum of human ailments including cancer, rheu-
matoid arthritis (RA), psoriasis, asthma, primary biliary cirrhosis, and is also as an immuno-
suppressant [1–4]. However, several studies have demonstrated the adverse effects of MTX in
long term or high dose treatment; one of the major concerns being its pro-oxidant and non-
specific action [5]. The average MTX levels in cerebrospinal fluid and serum is reported to be
17.1 μM and 779 μM respectively in various cancer patients treated with high-dose MTX [6].
Of late, Conway et al. [7] conducted a meta-analysis study involving randomized controlled tri-
als and demonstrated a significant correlation in the risk of lung disease in MTX-treated RA
patients. Another recent retrospective review describes the incidences of MTX withdrawal in
RA patients due to unacceptable adverse effects. The study claims that about 32.7% patients
experienced gastrointestinal problems, while 20.6% had nausea. Several cancer and RA patients
also experienced significant respiratory, hepatic and renal dysfunctionalities [8]. The MTX-
induced organ damage is attributed to oxidative stress due to excessive production of reactive
oxygen/nitrogen species (ROS/RNS) [9]. The circulatory MTX is shown to induce acute and
chronic augmentation in plasma homocysteine levels, which in turn is responsible for elevated
levels of ROS. It also induces depletion of glutathione (GSH) by diminishing the intracellular
NADPH levels and thus, altering redox homeostasis [10].
Lately, anemia and thrombocytopenia have been linked with MTX overdose or on pro-
longed treatment. Many studies report a significant case of thrombocytopenia among MTX-
treated RA and cancer patients [8], [11]. Thus, it is highly interesting to evaluate the mecha-
nism of action of MTX on platelets and their functions. Though the cytotoxic nature of MTX is
known, its effect on highly sensitive platelets is not clear. In addition, the role played by micro-
particles (MPs) (that are generated by activated and/or apoptotic platelets) in the propagation
of RA is well-known. Boilard et al. [12] have demonstrated the presence of elevated levels of
platelet-derived MPs in the synovial fluid from RA patients. Platelet-derived MPs were shown
to have a pro-inflammatory effect on synovial fibroblasts [12]. Despite the fact that platelets
are anuclear, they undergo apoptosis either naturally or upon external stimulation [13], [14].
Hitherto, several studies have demonstrated the mitochondria-mediated classical apoptotic
events. The elevated plasma levels of ROS are among the key factors responsible for premature
apoptosis of platelets [15], [16]. They are known to alter mitochondrial membrane potential
(Δψm) and trigger cytochrome c (cyt. c) release, which would activate caspases and communi-
cate phagocytic signals via phosphatidylserine (PS) externalization [17], [18]. Thus, MTX-
induced ROS generation may play a key role in platelet physiology and functions in RA
patients. Besides, studies have also reported the use of natural or synthetic small molecules to
prevent adverse effects of MTX. Many reports including our own have shown the platelet pro-
tective actions of small molecules [17], [19]. Hence, this study for the first time makes an
attempt to uncover the mechanistic action of MTX on platelet functions and survivability. We
examined the link between MTX-induced platelet apoptosis and JNK-mediated mitochondrial
damage. We also demonstrated the counter action of N-acetylcysteine (NAC) and N-acetylcys-
teine amide (NACA) on MTX-induced platelet apoptosis. Though NAC is a potent antioxi-
dant, its low bioavailability lead to the synthesis of NACA, which is more efficient than NAC in
all aspects including bioavailability [20].
Mitigation of MTX-Induced Platelet Apoptosis by NAC/NACA
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Materials and Methods
Chemicals/ Reagents
Calcium ionophore (A23187), NAC, NACA, leupeptin hydrochoride, 10-nonyl acridine orange
(NAO), dicumarol [3,3´-Methylene-bis(4-hydroxy-coumarin)], Mito-TEMPO, epinephrine,
adenosine diphosphate (ADP), monoclonal phosphotyrosine antibody (clone PT-66), dithio-
tritol, and all fluorescent dyes required to determine platelet apoptosis were from Sigma Chem-
icals, USA. Cyt. c antibody was from Epitomics, USA. z-DEVD-fmk, Caspase-3, Caspase-9,
Caspase-8, Bad, Bax, Bcl-2 and tBid antibodies were from Santa Cruz Biotechnology, Inc. USA.
COX IV, β-Tubulin, phospho-eIF2α (ser51), eIF2α, phospho-JNK 1/2 (Thr183/Tyr185) and
JNK 1/2 antibodies were from Cell Signaling and Technologies, Inc. USA. Collagen type-I was
from Chrono-log Corporation, USA. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was from HiMedia Laboratories, India. Lactate Dehydrogenase kit was from
Agappe diagnostics Ltd., India. Methotrexate was from Sisco Research Laboratories Pvt. Ltd.,
India. All other reagents were of analytical grade.
Preparation of platelet-rich plasma and washed platelets
Venous blood was drawn from healthy, non-smoking, drug-free human volunteers with writ-
ten consent and was approved by Institutional Human Ethical Committee (IHEC-UOM No.
40Res/2013-14), University of Mysore, Mysore. All methods were in accordance with IHEC
guidelines and the study was approved by IHEC (IHEC-UOM No. 40Res/2013-14), University
of Mysore, Mysore. The drawn blood was immediately mixed with acid citrate dextrose (ACD)
anticoagulant and processed as described previously to obtain platelet rich plasma (PRP) and
washed platelets [21]. The cell count was determined in both PRP and washed platelet suspen-
sions using a Neubauer chamber and adjusted to 5×108 cells/mL in the final suspension using
platelet poor plasma/Tyrode’s albumin buffer (pH 7.4).
Determination of platelet apoptotic markers
Platelet apoptotic markers like increase in ROS, intracellular calcium, peroxidation of cardioli-
pin and PS externailization in platelets were determined as described previously using Varios-
kan multimode plate reader (Thermo Scientifics, USA). Briefly, PRP and washed platelet
suspensions (5×106 cells/mL) were taken separately and treated with A23187 (10 μM) as
positive control or MTX in increasing doses (0–50 μM) and the final volume was made up to
200 μL with HEPES-buffered saline (HBS, pH 7.45) and incubated at 37°C for 1 h. For
inhibition studies, platelets were treated with MTX (50 μM) in presence or absence of
Dicumarol/ z-DEVD-fmk/ Mito-TEMPO/ NAC/ NACA at different doses (0–1000 μM). The
control (untreated) and treated platelets were then incubated with respective fluorescent
probes. Finally, cells were collected by centrifugation and fluorescence was recorded as
described previously [19], [22].
Flow cytometry
For flow cytometry analysis washed platelets (1×106 cells/mL) were stimulated with A23187
(10 μM) as positive control or MTX in increasing doses (0–50 μM) and incubated at 37°C for
1 h. For inhibition studies, platelets were treated with MTX (50 μM) in presence or absence
of NAC/NACA at different doses (0–1000 μM). After incubation, cells were stained using
CM-H2DCFDA, JC-1 and Annexin V-FITC, washed and analyzed by FACSVerseTM flow
cytometer (BD Biosciences, USA) [23–25].
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Western blot analysis
Washed platelets (1×108 cells/mL) were stimulated independently with MTX (0–50 μM) and
for inhibition studies, MTX treated platelets were incubated with different concentrations of
Mito-TEMPO/ Dicumarol/ z-DEVD-fmk/ NAC/ NACA. The samples were then incubated for
30 min to determine activation/expression levels of tyrosine phosphorylated proteins,
phospho-eIF2-α, eIF2-α, Bad, Bax, Bcl-2, tBid and caspase-8, 1 h for cyt. c, caspase-9 and -3
activation and 0–4 h for phospho-JNK1/2 and JNK1/2. Further, platelet suspensions were lysed
by adding 10 μL of HEPES buffer containing 2% SDS, 5 mM N-ethylmaleimide, 5 mM
Na3VO4, 10 mM EDTA and 10 mM PMSF. Following centrifugation, the supernatants were
separated on SDS-PAGE and electroblotted on to a PVDF membrane (MDI membranes,
Advanced Microdevices Pvt Ltd, India). Membrane was cut based on the molecular weight and
blocked using 5% BSA. Further, the blots were probed independently with respective
antibodies, developed by enhanced chemiluminescence method [19] and visualized using
western blot chemiluminescence imaging system (Alliance 2.1, Uvitec, UK).
Electron transport chain (ETC) assays
Assays for ETC complexes I, II, III and IV were performed as described accordingly [26].
Briefly, platelet mitochondrial fractions were treated with MTX in increasing doses (0–
100 μM) and for inhibition studies, platelets treated with MTX were incubated with different
doses of NAC/NACA (0–1000 μM) for 30 min at 37°C. Complex I activity was expressed as
mMNADH oxidized/min/mg protein, Complex II activity was expressed as mM dichlorophe-
nolindophenol (DCIP) reduced/min/mg protein, Complex III activity was expressed as mM
cyt. c reduced/min/mg protein and Complex IV activity was expressed as first-order rate con-
stant (k) of mM cyt. c oxidized/min/mg protein.
Measurement of γ-glutamyltransferase (GGT) activity
GGT activity in washed platelets was determined as described accordingly [27]. The results
were calculated using molar extinction coefficient of p-nitroanilide (9,900 M-1cm-1) at 405 nm
and expressed as mM p-nitroanilide formed/min/mg protein.
Microparticle isolation from platelets
Washed platelets (5×108 cells/mL) were treated independently with A23187 (10 μM) or MTX
in increasing doses (0–50 μM) and for inhibition studies, pre-loaded platelets with MTX
(50 μM) were incubated with different doses of NAC/NACA (0–1000 μM) for 1 h at 37°C.
After incubation, samples were gently mixed and to separate microparticles (MPs), samples
were centrifuged at 14,200×g for 15 min at 4°C and the supernatant thus obtained was
considered as MP-rich fraction [28]. Supernatants were used to determine coagulant activity.
Coagulant activity
The plasma coagulation property was determined according to the method of Condrea et al.
[29]. Normal human citrated plasma (200 μL) was incubated with different doses of MTX (0–
50 μM) and MP-rich fraction (20 μL), and the clotting time was recorded against a light source.
Platelet aggregation
Platelet aggregation was determined by turbidimetric method with a dual channel Chrono-log
model 700–2 aggregometer (Havertown, USA). Briefly, 250 μL of PRP was taken in siliconized
glass cuvette and pre-incubated for 3 min at 37°C with different concentrations of MTX (0–
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50 μM), and the aggregation was initiated by the addition of collagen (2 μg/mL)/ADP (5 μM)/
epinephrine (10 μM). The aggregation was then followed with constant stirring at 1200 rpm
for 6 min at 37°C [19].
MTT assay
MTT colorimetric assay was performed to assess the cell viability. PRP was treated indepen-
dantly with A23187 (10 μM) or different doses of MTX (0–50 μM). For inhibition studies,
platelets treated with MTX (50 μM) were incubated with different concentrations of NAC/
NACA (0–1000 μM). After 1 h of incubation 250 μM of MTT was added and incubated for
additional 3 h. Thereafter, MTT was removed and the remaining formazan crystals was
completely dissolved in DMSO. The absorbance at 570 nm was recorded using multimode
plate reader [15].
Measurement of LDH leakage
PRP was treated as described in the above section and platelets were pelleted by centrifuging at
1,700×g for 10 min. Supernatants were used to detect LDH release by using Agappe LDH kit,
according to the manufacturer’s protocol. The assay was performed in a time course of decrease
in NADH absorbance at 340 nm for 3 min using spectrophotometer (Beckman Coulter DU-
730, CA, USA) [15].
Protein estimation
Protein estimation was carried out according to the method of Lowry et al. [30] using BSA as
standard.
Statistical analysis
Results were expressed as mean ± SEM of five independent experiments. Statistical significance
among groups was determined by one way analysis of variance (ANOVA) followed by Tukey’s
test for comparison of means [n = 5, p/#< 0.05, p/##< 0.01, p/###< 0.001; : significant
compared to control. #: significant compared to MTX alone treated group].
Results
MTX-induced ROS generation and its inhibition by NAC/NACA
In order to understand whether MTX has any influence on platelet functions, initially platelets
treated with MTX were evaluated for endogenous generation of ROS. FACS analysis of MTX-
treated platelets showed significant increase in endogenous generation of ROS compared to
control (Fig 1A). Further, MTX displayed significant decrease in GSH/GSSG levels when com-
pared to control pointing out the oxidative stress in platelets (Fig 1B). GGT, whose upsurge is a
mark of cellular stress, was also found to be elevated in MTX-treated platelets (Fig 1C). How-
ever, no significant alteration in glutathione peroxidase and reductase activities was observed
(data not shown). Interestingly, treatment with NAC and NACA significantly abolished MTX-
induced ROS generation, restored GSH/GSSG levels and GGT activity (Fig 1A–1C).
Mito-TEMPO, a mitochondria-targeted ROS antagonist completely abolished MTX-
induced ROS production indicating that mitochondria are the major sources for ROS produc-
tion in platelets (Fig 1D). Therefore, effects of MTX on mitochondrial components of ETC
were assessed. MTX at 100 μM concentration reduced NADH: ubiquinone oxidoreductase
(Complex-I) activity up to 42% (Fig 1E) whereas, succinate: ubiquinone oxidoreductase (Com-
plex-II) activity was slightly reduced (Fig 1F). Furthermore, coenzyme Q: cytochrome c
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oxidoreductase (Complex-III) activity remained unaffected (Fig 1G); while there was a signifi-
cant reduction in the activity of cyt. c oxidase (Complex-IV) up to 50% upon exposure to
100 μMMTX (Fig 1H). Surprisingly, the presence of NAC and NACA significantly restored
the activities of complexes I and IV of ETC, confirming their protective role against MTX-
induced toxicities on platelets (Fig 1E and 1H).
MTX-induced mitochondrial dysfunction and its protection by NAC/
NACA
When cellular oxidative stress exceeds beyond its control the cells are destined to undergo apo-
ptosis, which includes Ca2+ion release, altered ΔCm, cyt. c release from mitochondria and
downstream apoptotic events. MTX significantly induced the release of Ca2+ from
endoplasmic reticulum (ER) (Fig 2A) and immunoblots of eIF2-α suggest that platelets were
under ER stress during MTX treatment (Fig 2B).
Altered ROS and intracellular calcium levels cause mitochondrial transition including dissi-
pation of ΔCm and peroxidation of cardiolipin. It was observed that MTX dose-dependently
increased peroxidation of cardiolipin (Fig 2C) and dissipated ΔCm (Fig 2D). Whereas, treat-
ment with NAC/NACA significantly restored Ca2+ levels, ER stress, cardiolipin peroxidation,
and ΔCm (Fig 2A–2D).
Fig 1. MTX altered ROS levels in platelets and its inhibition by NAC/NACA/Mito-TEMPO. A, FACS analysis of ROS generation in washed platelets
treated with MTX in presence or absence of NAC/NACA. B,GSH/GSSG ratio and (C) γ-Glutamyltransferase activity. D, Effect of Mito-TEMPO on MTX
induced ROS generation, expressed as percentage increase in DCF fluorescence. Effect of MTX in presence or absence of NAC/NACA on components of
mitochondrial electron transport chain, (E) Complex I-NADH: ubiquinone oxidoreductase activity (F) Complex II-succinate: ubiquinone oxidoreductase
activity (G) Complex III-coenzyme Q: cytochrome c-oxidoreductase activity and (H) Complex IV-cytochrome c oxidase activity. Values are presented as
mean ± SEM (n = 5). p*/#< 0.05, p**/##< 0.01, p***/###< 0.001; *: significant compared to control. #: significant compared to MTX.
doi:10.1371/journal.pone.0127558.g001
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MTX induces platelet apoptosis; protection by NAC/NACA
Peroxidized cardiolipin aids in the formation of mitochondrial permeability transition pore
(MPTP) through which cyt. c escapes into cytosol, which in turn induces caspase-3 activation
and finally PS externalization. MTX was found to induce cyt. c release from mitochondria to
cytosol, expression of cleaved caspases, particularly caspase-9 and -3 (Fig 3A). Recently it has
been demonstrated that activated caspases cleave variety of cellular substrates and thus expose
new sites on proteins for phosphorylation [31]. Supportively, platelets treated with MTX com-
prised of increased tyrosine-phosphorylated protein content (Fig 3B). MTT also significantly
induced PS scrambling, the final hallmark of apoptosis (Fig 3C). Interestingly, treatment with
NAC/NACA abrogated cyt. c release, caspase-9 and -3 activation, and PS externalization (Fig
3A–3C). Further, LDH release and MTT assays confirmed the cytotoxic effect of MTX on
platelets, whereas NAC/NACA proved to be protective against MTX-induced cytotoxic prop-
erties (Fig 3D and 3E). Besides, MTX treatment did not affect platelet aggregation stimulated
by collagen/ADP/epinephrine (S1 Fig).
MTX induces platelet apoptosis via JNK activation
In order to dissect the molecular mechanism through which MTX induces platelet apoptosis,
various apoptotic signaling pathways were probed. MTX-treated platelets exhibited time
dependent and concentration-dependent increase in phosphorylated form of JNK1/2. (Fig 4A).
The phosphorylated form of JNK activates Bad, Bax and inhibits Bcl-2, contributing towards
mitochondrial dysfunction. However, Dicumarol a JNK specific inhibitor significantly inhib-
ited JNK phosphorylation suggesting it to be a key event. MTX-treated platelets also showed
increased expression of Bad, Bax, and suppression of anti-apoptotic Bcl-2 proteins, which was
also reversed in presence of Dicumarol (Fig 4B).
Moreover, Dicumarol and z-DEVD-fmk also inhibited MTX-induced caspase-3 activation
suggesting that caspase-3 activation might be mediated by upstream JNK phosphorylation.
Fig 2. MTX altered ER stress andmitochondrial apoptotic markers and its inhibition by NAC/NACA. Effect of MTX in presence or absence of NAC/
NACA on (A) changes in intracellular calcium levels, (B) phospho-eIF2-α expression and (C) peroxidation of cardiolipin, (D) FACS analysis of ΔΨm
depolarization in washed platelets treated with MTX in presence or absence of NAC/NACA. Values are presented as mean ± SEM (n = 5), expressed as
percentage increase in (A) fura-2/AM and (C) NAO fluorescence. p*/#< 0.05, p**/##< 0.01, p***/###< 0.001; *: significant compared to control. #:
significant compared to MTX. Membrane was cut based on the molecular weight, probed with antibody of interest and band of interest were presented.
doi:10.1371/journal.pone.0127558.g002
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(Fig 4B and 4C). Mito-TEMPO, a specific mitochondrial ROS quencher significantly abolished
MTX-induced phosphorylation of JNK confirming that JNK activation was primed by mito-
chondrial ROS (Fig 4D). Additionally, NAC/NACA significantly decreased JNK activation,
restored Bax, Bad, tBid, Bcl-2 and Cas-8 levels in MTX-treated platelets (Fig 4E).
Finally, FACS data confirmed the protective effects of NAC/NACA in reducing PS external-
ization in MTX-activated platelets (Fig 5A). MTX-mediated PS externalization was also per-
formed in the presence of Mito-TEMPO, Dicumarol and z-DEVD-fmk. PS externalization was
significantly obliterated in the presence of Mito-TEMPO, Dicumarol and z-DEVD-fmk sug-
gesting, MTX-induced platelet apoptosis is driven by mitochondrial ROS-mediated JNK acti-
vation (Fig 5B–5D).
Besides, MTX did not alter plasma clotting time whereas, MP-rich fraction obtained from
MTX-treated platelets were able to significantly decrease plasma clotting time (Fig 5E). Alto-
gether, these findings suggest that MTX induces platelets apoptosis via JNK activation, and
treatment with NAC/NACA appeared to be promising in confronting MTX-induced platelet
apoptosis.
Discussion
MTX is an important therapeutic drug for a variety of human malignancies and autoimmune
disorders [32–34]. However, MTX is reported to repress the cellular antioxidant system,
thereby augmenting oxidative stress in many organs such as liver, kidney, central nervous sys-
tem and small intestine [35]. MTX is demonstrated to increase the amount of H2O2 and stimu-
late neutrophils, leading to the release of other free radicals causing cellular damage [36]. It
Fig 3. MTX induced platelet apoptosis and its inhibition by NAC/NACA. Effect of MTX in presence or absence of NAC/NACA/Dicumarol on (A) cyt. c
release frommitochondria to cytosol, activation of caspase-9 and caspase-3, (B) protein tyrosine phosphorylation, (C) PS externalization, (D) LDH release
and (E) MTT cell viability assay. B, Lane I: resting platelets (untreated), Lane II: platelets treated with A23187 (10 μM), Lane III: platelets treated with MTX
(50 μM), Lane IV: pre-loaded platelets with MTX (50 μM) and incubated with NAC (500 μM), Lane V: pre-loaded platelets with MTX (50 μM) and incubated
with NACA (50 μM). Values are presented as mean ± SEM (n = 5), expressed as percentage increase in (C) Annexin V-FITC fluorescence. COX IV and β-
Tubulin were used as loading control. p*/#< 0.05, p**/##< 0.01, p***/###< 0.001; *: significant compared to control. #: significant compared to MTX.
Membrane was cut based on the molecular weight, probed with antibody of interest and band of interest were presented.
doi:10.1371/journal.pone.0127558.g003
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reportedly hinders the remethylation of homocysteine resulting in elevated levels of homocys-
teine, causing ROS generation including H2O2 [37]. The elevated ROS play a key role in arbi-
trating apoptosis and cellular signaling pathways, which have been held responsible for MTX-
induced tissue damage [38]. Several RA and cancer patients treated with MTX are diagnosed
with significant respiratory and renal dysfunctionalities, neutropenia and thrombocytopenia
[39], [40]. Here we investigate the effect of MTX on anuclear platelets to understand whether
MTX can induce toxicity in platelets as they do in other cells or activate key signaling cascade
as an explanation to MTX-induced thrombocytopenia. We also demonstrate the mitigation of
MTX-induced platelet apoptosis and toxicities by potent antioxidants NAC/NACA, emphasiz-
ing the use of antioxidants as supplementary therapy in MTX treatment.
The hepatic and renal toxicities observed during MTX treatment, are deemed to be the
result of oxidative stress due to reduction in GSH content [41]. GGT cleaves GSH to glutamic
Fig 4. JNK activation by mitochondrial ROS in MTX-treated platelets and its reversal by NAC/NACA. A, Immunoblot showing the expression of
phospho-JNK in time- and concentration-dependent manner in MTX-treated platelets.B, Immunoblots showing the effect of Dicumarol on the expression
levels of phospho-JNK, Bcl-2, Bad, Bax, cyt. c, Cas-3 in MTX treated platelets. C, Immunoblots showing the effect of z-DEVD-fmk on the expression level of
Cas-3 in MTX-treated platelets.D, Immunoblots showing the effect of Mito-TEMPO on the expression levels of phospho-JNK in MTX-treated platelets. E,
Effect of NAC/NACA on the expression levels of phospho-JNK, Bcl-2, Bad, Bax, tBid and Cas-8 in MTX-treated platelets. F, Representative densitogram of
immunoblots present in panelA, B, C, D, and E. JNK and β-Tubulin were used as loading control. Membrane was cut based on the molecular weight, probed
with antibody of interest and band of interest were presented.
doi:10.1371/journal.pone.0127558.g004
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acid and cysteinylglycine and thus augments the levels of GGT in serum, an essential biochemi-
cal marker of early oxidative stress, in the joints, synovial fluid and spleen of MTX-treated RA
patients [42]. In the present study, although MTX did not augment the activities of glutathione
peroxidase and glutathione reductase, it was found to decrease the GSH/GSSG ratio and
increase GGT activity in platelets. This observation is particularly crucial in regard to the use of
MTX in RA patients, considering the key role played by activated platelets and platelet-derived
MPs in the pathophysiology of RA. NAC and NACA were able to restore the GSH/GSSG ratio
to normal and also impair the heightened activity of GGT; thus proving to be effective in pre-
venting MTX-induced oxidative stress at various stages.
Studies have demonstrated that MTX induces intestinal injury via ROS generation leading
to mitochondrial dysfunction [43]. Many of the crucial events in apoptosis are centered on
mitochondria, and that includes cyt. c release, changes in electron transport, loss of ΔCm and
altered cellular oxidation-reduction. Nearly, all functions of mitochondria are associated with
oxidative phosphorylation and energy coupling machinery located in the inner mitochondrial
membrane. It consists of the ETC complexes I, II, III and IV, ATP synthase, ubiquinone, and
cyt. c as electron transporters [26]. The ETC is considered a chief site of ROS generation, how-
ever, mitochondria are themselves vulnerable to oxidative damage, resulting in the impairment
of respiratory enzyme activities, and thus affecting ΔCm and further production of ROS. Mito-
chondrial ROS generation is the net effect of ROS production at the ETC and their riddance by
antioxidative enzymes. These two events rely greatly on the mitochondrial redox status, which
is in turn dynamically influenced by various physiological and pathological settings [35]. The
lipids, proteins, oxidative phosphorylation of enzymes, and mitochondrial DNA are all affected
by ROS, thus ensuing cell death via apoptosis or necrosis [44]. Cyt. c oxidase is the terminal
oxidase of the mitochondrial ETC, whose activity is also associated with apoptosis and has
been reported to be in the reduced state during mitochondria-driven apoptosis. The structure
and function of the enzyme is altered under different pathological conditions such as cancer,
neurodegenerative diseases, CVDs, diabetes etc. It is thought that cyt. c oxidase dysfunction is
most often associated with increased mitochondrial ROS production and cellular toxicity [45].
Fig 5. A, Effect of NAC/NACA onMTX-induced PS externalization. Effect of (B) Dicumarol (C) z-DEVD-fmk and (D) Mito-TEMPO on MTX induced PS
externalization on washed platelets. (E) Effect of microparticle-rich fraction on plasma clotting time obtained fromMTX-treated platelets. Values are
presented as mean ± SEM (n = 5), expressed as percentage increase in (B-D) Annexin V-FITC fluorescence. p*/#< 0.05, p**/##< 0.01, p***/###< 0.001; *:
significant compared to control. #: significant compared to MTX.
doi:10.1371/journal.pone.0127558.g005
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Cardiolipin oxidation is in recent times regarded as a significant factor not only in mito-
chondrial dysfunction, but also in the early stages of the mitochondrial apoptotic pathway [46].
Cardiolipin is an early target of ROS; oxidized cardiolipin flips from the inner to the outer
mitochondrial membrane paving way for the formation of MPTP in the presence of Ca2+
released from ER and Golgi in response to stress, thus leading to leakage of cyt. c into the
cytosol [47]. It has been reported that MTX mobilizes intracellular Ca2+ stores and that the
their exhaustion might be responsible for the hepatotoxic and apoptotic effects of MTX [48].
From the results of the current study, it is clear that MTX induces apoptosis in platelets as
evidenced by elevated activity of ETC enzymes such as NADH:ubiquitin-oxidoreductase
causing increased ROS. It is also observed that MTX-induced phosphorylation of eIF2α causes
ER stress, which in turn causes increased cytosolic Ca2+. Increased levels of ROS and Ca2+
further results in decreased ΔCm, cyt. c oxidase, augmented cardiolipin peroxidation as well as
increased concentration of cytosolic cyt. c. These results are in line with a recent study by Kolli
et al. [43], which demonstrated that MTX-induced mucositis is linked to the alteration of
mitochondrial structure resulting in loss of function, and diminished activities of ETC
components in enterocytes. The pro-apoptotic nature of MTX in platelets, was further
confirmed by increased caspase-9 and -3 activities, PS externalization, protein tyrosine
phosphorylation, as well as MTT and LDH assays. All the above-mentioned MTX-induced
platelet apoptotic events were suppressed by NAC and more potently by NACA, underscoring
the anti-apoptotic efficacy of these compounds. Though, MTX significantly promotes
apoptosis in platelets, it neither affected various agonist-induced platelet aggregation nor on
blood coagulation, suggesting that MTX does not activate platelets but rather triggers them to
undergo apoptosis.
Investigation of the mechanism of MTX-induced platelet apoptosis apparently demon-
strated the involvement of JNK signaling. MTX-induced ROS production is considered to be
the most prominent mitochondrial inducer of JNK signaling in HeLa cells [49]. Activated JNK
is reported to induce Bax, Bad and tBid leading to ΔCm dissipation and cyt. c release causing
apoptosis in many nucleated cells [50]. JNK phosphorylation causes dephosphorylation of Bad
(Ser136) and Bcl-2, and dissociates Bad from Bcl-XL or Bcl-2, resulting in elevated levels of
Bad and Bcl-2 [51]. Here we demonstrate that MTX apparently induces phosphorylation of
JNK, which in turn dephosphorylate Bad and elevate the levels of pro-apoptotic Bcl-2 family
proteins, particularly Bax, Bad and tBid. This causes decreased ΔCm with cyt. c release and cas-
pase activation in platelets leading to apoptosis. Use of specific inhibitor for JNK clearly dem-
onstrates that phosphorylation of JNK is a key in the MTX-driven apoptosis in platelets. In
addition, Mito-TEMPO, mitochondria-targeted ROS antagonist completely abolished MTX-
induced ROS production along with phosphorylation of JNK, and downstream PS externaliza-
tion indicating that mitochondria are the major sources for ROS production in platelets and is
responsible for MTX-induced platelet toxicity. NAC/NACA treatment effectively suppressed
JNK-mediated activation of Bcl-2 family proteins by MTX as well as the subsequent apoptotic
events. NAC being a precursor of cellular L-cysteine and reduced GSH, also scavenges free rad-
icals by interacting with ROS [52]. In the current scenario, NAC is assumed to scavenge free
radicals generated by impaired electron transport during MTX treatment and also increase cel-
lular reduced glutathione content. The obtained results clearly suggest that mitochondrial ROS
are the key mediators of MTX-induced apoptosis. Thereby, NAC and its derivative NACA
intercede at the root cause and regulate MTX-induced apoptosis. Finally, it is demonstrated
that MTX promotes apoptosis in platelets by activation of ROS-JNK-mediated mitochondrial
damage and NAC/NACA protects platelets by increasing reducing equivalent levels and scav-
enging ROS.
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Besides, when platelets are activated or undergo apoptosis, the normal asymmetrical distri-
bution of lipids between the inner and outer leaflets of a plasma membrane is disturbed, result-
ing in blebbing of plasma membrane and shedding of procoagulant MPs. Platelet-derived MPs
(PMPs) are a pool of bioactive effectors and are able to act as intercellular messengers, regulate
inflammation, and influence vascular functions, apoptosis and cellular cross talk. PMPs play a
significant role in the pathogenesis of RA, cancer metastasis and other vascular diseases [53].
Conclusion
Despite the therapeutic potential of MTX as anti-rheumatic and anti-cancer drug, recent
reports demonstrate that it leads to an oxidative catastrophe. MTX, being a pro-oxidant, aggra-
vates endogenous ROS production at the cellular level and provokes oxidative damage to liver,
kidney, and even to central nervous system. Notable incidences of thrombocytopenia in MTX-
treated RA and cancer patients convey that MTX in the circulation along with the augmented
levels of cellular ROS that have infiltrated into circulation also affect blood components. Here,
we appraise the pro-apoptotic action of MTX on platelets and its inhibition by NAC, a clini-
cally approved potent thiol antioxidant and its derivative NACA. MTX remarkably accelerates
ROS-mediated oxidative stress in platelets triggering apoptotic events via JNK-mediated mito-
chondrial damage. The treatment of NAC/NACA efficiently restrains MTX-induced oxidative
stress and apoptosis of platelets. The present study for the first time reports the mechanism of
action of MTX on platelets and establishes a connection with thrombocytopenia in MTX-
treated RA/cancer patients. The results of the present study pose apprehensions in the involve-
ment of pro-oxidants in therapeutic regimen of human ailments, as it might cause added stress
to the already ailing system and may lead to severe secondary complications. It may even lead
to resurgence of the disease owing to MP generation. The unwarranted levels of MPs in circula-
tion might also result in the manifestation of yet another disease and this vicious cycle seems to
go on and on. Furthermore, our study also underpins the use of clinically potent antioxidants
as auxiliary to MTX treatment regime considering the significant role played by the latter in
cancer and RA treatment.
Supporting Information
S1 Fig. Effect of MTX on platelet aggregation induced by (A) Collagen (B) ADP (C) Epi-
nephrine. [Blue trace- Collagen/ADP/Epinephrine alone, black trace- MTX 10 μM, brown
trace- MTX 25 μM, green trace- MTX 50 μM] (D) Graphical representation of the data show-
ing percentage platelet aggregation. Values are presented as mean ± SEM (n = 5).
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